MediciNova, Inc.
NASDAQ:MNOVBiotechnology
-$0.02 today
- Market cap
- $68.14M
- Beta
- 0.62
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.24
Volume 0.12M
Average 0.04M
MNOV Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
MediciNova, Inc.NASDAQ: MNOV
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $407.76K rose 42.6% year over year, ahead of the -24.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 20.5% from the prior quarter. Over 3 fiscal years it compounded at +8.9% a year.
Context
- Stock-based compensation amounted to 202.4% of revenue in FY2025.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +42.6% holds above the trailing-twelve-month pace of -24.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 829.1K USD
- Year-over-year change
- -30.4%
- 4-year CAGR
- -16.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 829.1K | -30.4% |
| FY2024 | 2024-12-31 | 1.19M | +67.7% |
| FY2023 | 2023-12-31 | 710.71K | +10.6% |
| FY2022 | 2022-12-31 | 642.52K | -62.6% |
| FY2021 | 2021-12-31 | 1.72M | — |
Stock-Based Compensation vs competitors
How MNOV compares with its peers on the latest reported figures
- MNOV's LTM Mar 2026 stock-based compensation of $950.91K is the 10th largest of the 11 companies compared; the peer median is $9.05M.
- Its year-over-year change of -24.7% is the 4th highest of 11, against a peer median of -28.9%.
- Stock-based compensation amounts to 159.4% of revenue for MNOV, versus a peer median of 75.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.45M | -34.1% | +7.7% | 33.9% | |
| LTM Mar 2026 | $13.93M | -47.2% | -30.3% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $13.11M | -11.0% | +88.9% | — |
| LTM Mar 2026 | $11.29M | +44.4% | +3.8% | — | |
| LTM Mar 2026 | $10.76M | -2.0% | +37.0% | 117.7% | |
| LTM Mar 2026 | $7.34M | -25.5% | -15.1% | 2.9% | |
CBUSCibus, Inc. | LTM Mar 2026 | $7.26M | -32.3% | +27.0% | 169.4% |
| LTM Mar 2026 | $5.81M | -25.3% | -16.6% | — | |
| LTM Mar 2026 | $4.16M | -75.9% | -2.7% | — | |
| LTM Mar 2026 | $950.91K | -24.7% | +8.9% | 159.4% | |
| LTM Mar 2026 | $465K | -90.1% | -10.6% | — | |
| Peer median (excluding MNOV) | $9.05M | -28.9% | +0.5% | 75.8% | |
Competitors are the stored peer set for MNOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.13M) | (14.07M) | (8.57M) | (11.05M) | (12M) |
| Depreciation & Amortization | 26.15K | 17.71K | 20.3K | 21.08K | 20.1K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.72M | 642.52K | 710.71K | 1.19M | 829.1K |
| Change in Working Capital | (1.21M) | 334.1K | 111.99K | (979.56K) | 1.17M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.03M) | 329.01K | 19.24K | (312.35K) | 459.87K |
| Other Working Capital | (181.42K) | 5.09K | 92.75K | (667.21K) | 705.15K |
| Other Non-Cash Items | 216.93K | 163.19K | 297.49K | 173.32K | 173.68K |
| Operating Cash Flow | (9.38M) | (12.91M) | (7.43M) | (10.64M) | (9.81M) |
| Capital Expenditures | (28.73K) | (5.01K) | (21.3K) | (895) | 0 |
| Acquisitions (Net) | 0 | 5.01M | 0 | 0 | 0 |
| Purchases of Investments | 0 | (59.88M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 19.88M | 39.93M | 0 | 0 |
| Other Investing Activities | 0 | (5.01M) | 0 | 198 | (2.9K) |
| Investing Cash Flow | (28.73K) | (40.01M) | 39.91M | (697) | (2.9K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 20.89M | 7.92K | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (112.26K) | 0 | 0 | 0 | 244.02K |
| Financing Cash Flow | 20.78M | 7.92K | 0 | 0 | 244.02K |
| Effect of Forex Changes | 26.55K | (16.81K) | 17.27K | 3.96K | 15.68K |
| Net Change in Cash | 11.39M | (52.93M) | 32.49M | (10.64M) | (9.55M) |
| Free Cash Flow | (9.41M) | (12.92M) | (7.45M) | (10.64M) | (9.81M) |
MediciNova, Inc.
NASDAQ:MNOV
Intrinsic Alpha fair value
Locked
Current Price
$1.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.